Mainz Biomed NV
F:4TO
Balance Sheet
Balance Sheet Decomposition
Mainz Biomed NV
Mainz Biomed NV
Balance Sheet
Mainz Biomed NV
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
0
|
0
|
9
|
17
|
7
|
6
|
|
| Cash |
0
|
0
|
9
|
17
|
7
|
6
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
1
|
0
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
1
|
1
|
|
| Total Current Assets |
0
|
0
|
10
|
18
|
9
|
8
|
|
| PP&E Net |
0
|
0
|
0
|
2
|
3
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
2
|
3
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
1
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
3
|
3
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
1
N/A
|
1
-7%
|
10
+1 399%
|
20
+102%
|
15
-24%
|
13
-14%
|
|
| Liabilities | |||||||
| Accounts Payable |
0
|
0
|
1
|
1
|
6
|
2
|
|
| Accrued Liabilities |
0
|
0
|
0
|
2
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
5
|
1
|
|
| Other Current Liabilities |
0
|
0
|
0
|
1
|
1
|
2
|
|
| Total Current Liabilities |
0
|
1
|
1
|
4
|
9
|
6
|
|
| Long-Term Debt |
1
|
1
|
0
|
1
|
1
|
1
|
|
| Other Liabilities |
1
|
2
|
2
|
1
|
2
|
0
|
|
| Total Liabilities |
3
N/A
|
3
+28%
|
4
+8%
|
6
+67%
|
12
+98%
|
7
-41%
|
|
| Equity | |||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
1
|
|
| Retained Earnings |
2
|
3
|
7
|
25
|
48
|
63
|
|
| Additional Paid In Capital |
0
|
0
|
13
|
39
|
52
|
69
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Equity |
2
N/A
|
3
-41%
|
6
N/A
|
14
+122%
|
3
-77%
|
6
+86%
|
|
| Total Liabilities & Equity |
1
N/A
|
1
-7%
|
10
+1 399%
|
20
+102%
|
15
-24%
|
13
-14%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
1
|
2
|
|